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Efficacy and safety of losartan in the treatment of hypertension in
renal transplant recipients. Arterial hypertension, which repre-
sents a common problem in patients with renal transplant, con-
tributes to the cardiovascular morbidity and mortality of these
patients. The most usual immunosuppressive drugs (cyclosporine
and FK-506) collaborate on the development of hypertension.
Calcium channel blockers are the most habitually used antihyper-
tensive drugs in this population, although its long-term hemodi-
mamycs effects could be deleterious especially in transplanted
patients with chronic graft nephropathy. Losartan, a specific
blocker of angiotensin II (AT1) receptors, has demonstrated a
potent antihypertensive effect with a good safety and tolerance
profile. The glomerular effects of losartan could be useful in
transplanted patients. The present open, prospective and multi-
center study evaluated the efficacy and safety of losartan in the
treatment of hypertension in a group of patients with a renal
transplant. Seventy-six patients with systolic blood pressure $ 140
and/or diastolic blood pressure $ 90 mm Hg, and/or patients on
therapy with one antihypertensive drug and related side effects
were included. After inclusion, therapy with losartan 50 mg/24 hr
was started, discontinuing the previous antihypertensive therapy
and/or therapy which caused the side effects. At four weeks, if
blood pressure (BP) was not controlled, hydrochlorothiazide 25
mg or furosemide 40 mg/24 hr was added. At baseline and at
weeks 2, 4, 8 and 12, the following parameters were monitored:
BP, creatinine, hematocrit, hemoglobin, glucose, ions, uric acid,
cholesterol, triglycerides, bilirubin, SGOT, SGPT, GGT, LDH,
calcium, phosphate, alkaline phosphatase, proteinuria, and both
cyclosporine and FK-506 levels in whole blood. Sixty-seven pa-
tients completed the 12-week study period. Mean blood pressure
decreased from 113 6 10 to 102 6 9 mm Hg at the end of the
study (P , 0.0001); 38 of the 67 patients (56.7%) who completed
the study had a SBP lower than 140 mm Hg and a DBP lower than
90. These blood pressures were obtained in 30 patients on
monotherapy with losartan (78.9%). Proteinuria decreased signif-
icantly at week 4 and was confirmed at week 12, especially in
patients with proteinuria $ 300 mg/24 hr. Nine patients were
withdrawn during the study period for different reasons. Serum
creatinine showed a slight, non-clinically significant increase at
week 4, remaining stable until the end of the study. Two patients
developed a mild normocytic anemia, and three others presented
a mild impairment of pre-existent anemia. No interactions with
cyclosporine or FK-506 were described. These results indicate
that losartan is effective in reducing BP in hypertensive patients
with a renal transplant. It has a good tolerance profile and does
not interfere with immunosuppressive therapy.
Hypertension is common after renal transplantation oc-
curring in more than 50% of successfully transplanted
patients. Acute and chronic rejection episodes, immuno-
suppressive therapy, recurrent renal disease, native kidney
diseases and renal artery stenosis have been implicated as
causing post-transplant arterial hypertension [1, 2]. The use
of calcineurin inhibitors (cyclosporine and FK-506) as a
basic immunosuppressive therapy has aggravated the prob-
lem of hypertension. With the use of cyclosporine therapy,
the prevalence of hypertension is consistently around 75%,
and the prevalence of severe hypertension has been re-
ported to be 20% [3]. Hypertension in these patients is
characterized by sodium retention, enhanced sympathetic
nervous system activity, renal vasoconstriction and rela-
tively lower levels of plasma renin [4]. For many years it has
been known that hypertension, as a cardiovascular risk
factor, is associated with poor patient survival and lower
graft survival, although the nature of this relationship has
not been clearly delineated. Recently, Opelz, Wujciak and
Ritz demonstrated a striking association between systolic
(SBP) and diastolic blood pressure (DBP) levels and kidney
graft survival, and found that post-transplant blood pres-
sure was a highly significant predictor of long-term graft
survival. [5].
Optimum management of post-transplant hypertension
remains to be defined. Calcium channel blockers have
proven to be effective in ameliorating cyclosporine-associ-
ated nephrotoxicity, controlling hypertension and prevent-
ing post-transplant acute tubular necrosis [6]. It has been
proposed that the effect of angiotensin converting enzyme
(ACE) inhibitors on renal hemodynamics may prevent the
progression of renal glomerulosclerosis and chronic dete-
rioration of renal function [7]. In renal transplant recipi-
ents, glomerular capillary hypertension may occur due to
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systemic arterial hypertension, reduced nephron mass, im-
munosuppressive therapy (calcineurin inhibitors) and
chronic graft rejection. ACE inhibitors may not only effec-
tively reduce systemic hypertension, but also exert a bene-
ficial intrarenal hemodynamic effect, although as yet there
are no conclusive reports in the literature [8].
Losartan is a potent, orally active non-peptide blocker of
angiotensin II (Ang II) receptors. It is the first of a new
class of drugs to be introduced for clinical use in hyperten-
sion. This novel agent binds competitively and selectively to
the Ang II receptor (AT1), thereby blocking any Ang
II-induced physiological effects. Losartan clearance is
mainly extrarenal, whereas its active metabolite, E-3174, is
excreted by the renal and extrarenal routes alike. There are
no significant changes in plasma levels of active metabolite
in patients with renal impairment or under dialysis [9].
Clinical trials have shown that losartan has a safety and
tolerance profile comparable to placebo in hypertensive
patients [10]. In patients with renal impairment, including
those on hemodialysis, no substantial changes were seen in
serum potassium or creatinine levels nor in the creatinine
clearance. In addition, the blood pressure lowering effect of
losartan is accompanied by a significant reduction in pro-
teinuria in patients with chronic renal insufficiency [11].
There are few data available on the use of losartan in renal
transplant recipients, although it could represent a useful
and effective drug for treating hypertension and preventing
renal failure. The aim of this study was to test the efficacy
and safety of losartan in the treatment of arterial hyperten-
sion in renal transplant recipients, with a special emphasis
in renal function and proteinuria.
METHODS
Study design
The study consisted of a 12-week active treatment period
in which eligible patients were started on losartan, 50 mg
once daily. In patients previously treated with an antihy-
pertensive drug, a minimum washout period of one week
was required prior to inclusion in the study. Titration to
losartan 50 mg plus hydrochlorothiazide 25 mg or furo-
semide 40 mg was indicated for patients whose DBP
remained at or above 90 mm Hg at week 4. Titration to
losartan 100 mg was indicated at week 8 if DBP was 90 mm
Hg or greater.
Patient population
Seventy-six transplanted patients with arterial hyperten-
sion were recruited at eight renal transplant units in Spain.
All patients were at least 18 years of age and had no
suspected or documented renal artery stenosis. The demo-
graphic data of patients are given in Table 1. No patient
had a serum creatinine over 3 mg/dl, serum potassium
above 5.5 mEq/liter, or other severe concomitant disease or
suspected active infection. The patients eligible for inclu-
sion were those with a DBP $ 90 mm Hg and/or a SBP $
140 mm Hg in two or more readings performed at least
three days apart, and patients with side effects due to
current antihypertensive medication.
Study variables
Blood pressure and heart rate were measured at four-
week intervals during the treatment period. Blood and
24-hour urine samples were obtained before the study and
at 4, 8 and 12 weeks during losartan treatment for routine
fasting hematology, blood chemistry, plasma cyclosporine
levels, urinalysis and total proteinuria determination. A
partial blood chemistry for creatinine measurement was
also performed at week 2.
Statistical analysis
Values measured 2, 4, 8 and 12 weeks after treatment
were compared to those obtained before treatment. A
paired Student’s t-test was used to compare quantitative
variables. Wilcoxon signed rank test was used for quantita-
tive non-normal variables (Shapiro-Wilks test) and for
ordinal scale qualitative variables. Similarly, a McNemar
test was used for dichotomic variables, in order to compare
the percentages obtained at 2, 4, 8 and 12 weeks with those
obtained at baseline. A value of P , 0.05 was considered
significant; quantitative results are expressed as mean 6 SD.
RESULTS
A total of 67 patients completed the full 12 weeks of the
study period.
Efficacy
Mean blood pressure decreased from 113 6 10 to 102 6
9 mm Hg at the end of the study, P , 0.0001 (Table 2).
Systolic and diastolic blood pressure decreased significantly
from week 4. From this time, both SBP and DBP continued
to decline until week 12 (Fig. 1). Thirty-eight out of the 67
patients (56.7%) who completed the study had a SBP lower
than 140 mm Hg and a DBP lower than 90 mm Hg. These
Table 1. Demographics
Characteristics N 5 76
Sex
Male 50
Female 26
Reasons for inclusion
Uncontrolled BP 19
Side effect 57
Reasons of renal trasplant
Glomerulonephritis 27
Polycystic kidney disease 16
Interstitial nephritis 9
Other 24
Post-transplant follow-up
,1 year 27
1–3 year 20
.3 year 29
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blood pressures were obtained in 30 patients with losartan
monotherapy (78.9%).
Proteinuria. A strong positive effect was observed in
proteinuria at week 4, with a progressive decline until the
end of the study. In fact, after 12 weeks of losartan,
proteinuria decreased from 1.05 6 2.0 g/24 hr to 0.54 6 1.1
g/24 hr, P 5 0.04 (Table 2)
Safety
Overall, losartan tolerability was excellent. Nine patients
(12%) were withdrawn during the study period for different
reasons (Table 3).
Renal function. Mean serum creatinine showed a slight,
non-clinically significant increase at week 4, and then
remained stable (Fig. 2). Also, serum potassium increased
mildly at week 4 without any relevance (Fig. 3). After week
8, these two parameters remained stable. Transient hyper-
kalemia, defined as serum potassium levels .5.5 mEq/liter,
occurred in four patients, one at week 4, two at week 6, and
one at week 8. At week 12, all patients had a serum
potassium level lower than 5.5 mEq/liter. In three patients,
losartan was discontinued due to a slight increase in serum
creatinine, being in one case less than 1 mg/dl. In addition,
five patients had a mild increase in creatinine that did not
require discontinuation from the treatment.
In two cases, a mild normocytic anemia was reported,
and in three other patients a mild impairment of pre-
existent anemia was also reported. No graft failures were
reported during the study.
Fig. 1. Mean change from baseline in diastolic (DBP) and systolic (SBP)
blood pressure at weeks 4, 8, 12 (*P < 0.001).
Fig. 2. Mean change from baseline in creatinine at weeks 4, 8, 12 (*P <
0.0002; #NS vs. week 8).
Table 2. Changes in the mean parameters by week
Parameters N Baseline Week 4 Week 8 Week 12
SBP 67 156 6 17 147 6 18 143 6 16 142 6 14
P value
(Wilcoxon)
0.0002a 0.0001a 0.0001a
DBP 67 92 6 9 87 6 12 84 6 10 82 6 8
P value
(Wilcoxon)
0.0016a 0.0001a 0.0001a
Mean BP 67 113 6 10 107 6 13 104 6 11 102 6 9
P value
(Wilcoxon)
0.0001a 0.0001a 0.0001a
Creatinine 66 1.64 6 0.5 1.64 6 0.5 1.73 6 0.5 1.75 6 0.6
P value
(Wilcoxon)
0.1108 0.0002a 0.0001a
Potassium 64 4.3 6 0.5 4.5 6 0.6 4.4 6 0.5 4.5 6 0.5
P value
(Wilcoxon)
0.0001a 0.0065a 0.0017a
Hemoglobin 65 13.6 6 2.4 13.4 6 2.1 13.2 6 2.1 13.2 6 2.0
P value
(Student’s t)
0.0271a 0.0084a 0.0299a
Proteinuria 44 1.05 6 2.0 0.53 6 1.0 0.51 6 1.1 0.54 6 1.1
P value
(Wilcoxon)
0.0967 0.0222a 0.0403a
CsA levels 55 154 6 52.0 152 6 55.2 156 6 56.1 159 6 49.3
P value
(Student’s t)
0.7020 0.7398 0.3564
CsA dose 57 211 6 67 210 6 66 204 6 68 206 6 64
P value
(Student’s t)
0.2890 0.0362a 0.0529
FK-506 levels 7 12.0 6 3.7 10.9 6 2.6 10.0 6 3.0 9.5 6 1.3
P value
(Student’s t)
0.3738 0.3578 0.1873
FK-506 dose 7 9.2 6 3.0 8.3 6 2.6 7.7 6 2.1 7.6 6 2.2
P value
(Student’s t)
0.1560 0.0663 0.0382a
a P , 0.05 versus baseline
Table 3. Reasons for drop out
Probably related to losartan
Increase of creatinine 3
Not related to losartan
Acute rejection 1
CsA toxicity 1
Bradycardia 1
CVA 1
Cephalea 1
Unwilling of patient 1
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Interaction with immunosuppressive drugs. Blood levels
and doses of cyclosporine and FK-506 did not significantly
change during the study period.
No significant changes were seen in total serum choles-
terol, triglycerides, ALAT, ASAT, LDH, or bilirubin.
DISCUSSION
This study clearly shows a satisfactory control of arterial
hypertension in this high risk group of renal transplant
patients. Blood pressure was well controlled in most of the
patients, and in a majority of them with losartan mono-
therapy. Although this study only lasted 12 weeks and could
be considered a pilot study, a promising effect on protein-
uria was observed. Proteinuria significantly decreased in
the whole group. Moreover, in the group of patients with
higher proteinuria (.300 mg/24 hr) this effect was more
prominent. The tolerance of losartan was satisfactory, and
no serious side effects were recorded. A slight increase in
serum creatinine was observed and only three patients were
dropped out for this reason. The increase in serum creati-
nine is secondary to the change in the glomerular hemody-
namics, with a transient decrease in GFR. Serum potassium
also increased slightly in four patients, but in none of them
led to a discontinuation of losartan. Follow-up serum
creatinine and potassium levels returned to baseline in
most patients. Anemia and/or an exacerbation of a pre-
existing anemia were also recorded as side effects in five
patients. In the entire group, hemoglobin levels and hemat-
ocrit decreased slightly, but without clinical significance.
This side effect is very common with the use of ACE
inhibitors; it has been described in 30% of renal transplant
patients treated with these agents [12].
The management of hypertension in these high-risk
patients requires individualization of treatment and partic-
ular consideration of safety and tolerability, as well as
having an ability to not interfere with the immunosupres-
sive drugs routinely used in this special condition. In fact,
the use of drugs that potentially modified the therapeutic
blood levels of the immunosupressive treatment could
affect, in one hand, the graft survival by inducing high levels
of the calcineurin inhibitor and nephrotoxicity, or on the
other hand, by promoting low levels inducing graft rejec-
tion. Our data gave us further information about this
particular population. No adverse events related with the
immunosuppressive treatment was observed. The combina-
tions of losartan with cyclosporine or FK-506 did not
significantly modify the levels or the doses of these drugs.
High blood pressure places a kidney graft recipient at
risk for cardiovascular morbidity and mortality and in-
creased systemic hypertension, which is both a cause and a
consequence of renal disease. Hypertension is an important
risk factor contributing to the progression of renal failure.
Calcium antagonists are currently considered antihyperten-
sive agents of choice, and they are able to reverse cyclo-
sporine-induced renal vasoconstriction in animals [13].
Long-term studies in cyclosporine-treated patients have
shown that calcium antagonists are more effective than
b-blockers or other antihypertensive drugs [14]. However,
the glomerular hemodynamic effects of calcium antagonists
and the recently described proteinuric effect of some of
them could be deleterious in the long-term follow-up,
especially in patients with chronic graft nephropathy and
hyperfiltration syndrome [15].
The intrarenal renin-angiotensin system plays an impor-
tant role, not only in the regulation of glomerular hemo-
dynamics, but also in growth and sclerosis [16]. On the
other hand, ACE inhibitors and AT1 receptor antagonists
attenuate progressive glomerulosclerosis and interstitial
fibrosis in animal studies [17]. Recently, a link between Ang
II and transforming growth factor-b (TGF-b) was demon-
strated in a study showing that stimulation by Ang II of
extracellular matrix protein synthesis in rat glomerular
mesangial cells is mediated by increased TGF-b synthesis
and conversion from the latent to active form [18]. TGF-b
is considered a key fibrogenic cytokine implicated in the
fibrosis of a number of chronic diseases of the kidney and
other organs [19]. There is also evidence to suggest that the
renin-angiotensin system is activated in chronic cyclospor-
ine nephrotoxicity and chronic graft nephropathy [20]. The
demonstration that ACE inhibitors and AT1 receptor
blockers could decrease the synthesis and activation of
TGF-b [20] further support the idea of the usefulness of
these drugs for the treatment of hypertension in renal
transplant recipients. Based on the promising preliminary
results of our study with losartan, it seems reasonable to
explore the potential of losartan in a randomized, double-
blind long-term study as a treatment for the prevention of
chronic graft nephropathy.
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